Raymond James Initiates Coverage On Trevi Therapeutics with Outperform Rating, Announces Price Target of $9
Portfolio Pulse from Benzinga Newsdesk
Raymond James has initiated coverage on Trevi Therapeutics with an Outperform rating and set a price target of $9.
August 30, 2024 | 12:46 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Raymond James has initiated coverage on Trevi Therapeutics with an Outperform rating and a price target of $9, indicating a positive outlook for the stock.
The initiation of coverage with an Outperform rating and a specific price target of $9 by a reputable analyst firm like Raymond James is likely to positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100